image: Image Caption: Protein structure of mammalian SETD2. Image link: https://ars.els-cdn.com/content/image/1-s2.0-S2352304225001114-gr1_lrg.jpg
Credit: Genes & Diseases
The emerging role of SETD2 in regulating immune cell function is shedding light on potential therapeutic strategies for a range of immune-related diseases. As a key methyltransferase, SETD2 facilitates the trimethylation of lysine 36 on histone H3 (H3K36me3), a modification crucial for maintaining genomic stability and regulating gene transcription. Recent discoveries indicate that SETD2 not only influences tumorigenesis but also plays a pivotal role in the development, differentiation, and function of immune cells.
SETD2's involvement in the immune system spans across both innate and adaptive immunity. It has been found to be essential in the self-renewal and differentiation of hematopoietic stem cells (HSCs), maintaining a balance critical for immune homeostasis. The loss of SETD2 in HSCs can lead to genome instability, increased differentiation towards progenitors, and HSC exhaustion. This disruption not only impairs immune function but also poses a risk of malignant transformation.
Within the innate immune response, SETD2 has a significant impact on macrophage polarization. It inhibits the M1 macrophage activation pathway by suppressing hypoxia-inducible factor 1-alpha (HIF-1α), thereby reducing inflammatory responses. Conversely, reduced levels of SETD2 are linked to increased M1 polarization and glycolytic activity, which could exacerbate conditions like acute lung injury and osteomyelitis. Furthermore, SETD2 expression in mast cells has been shown to mitigate systemic mastocytosis, where its loss can lead to advanced forms of the disease.
SETD2 also plays a critical role in the adaptive immune system, particularly within T cell development and function. The absence of SETD2 impairs T cell receptor (TCR) recombination, leading to developmental arrest and T cell lymphopenia. Additionally, SETD2 influences the balance between Treg and Th17 cell differentiation, where it promotes Treg stability while suppressing pro-inflammatory Th17 responses. Such regulatory effects are crucial for controlling autoimmune reactions and maintaining immune tolerance.
In B cell biology, SETD2 is indispensable for immunoglobulin gene rearrangement, crucial for antibody diversity and adaptive immunity. Loss of SETD2 leads to defective V(D)J recombination, hampering B cell development and predisposing cells to lymphomagenesis. Moreover, germinal center B cells with reduced SETD2 function exhibit impaired DNA damage sensing, promoting B-cell lymphoma progression.
As research advances, understanding the mechanistic pathways regulated by SETD2 will unlock new possibilities for therapeutic intervention. Targeting SETD2 could potentially modulate immune cell functions, offering novel treatments for autoimmune diseases, inflammatory conditions, and hematological malignancies.
# # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4
Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )
# # # # # #
Reference
Longmin Chen, Yuan Zou, Yan Dong, Tian Hong, Qianqian Xu, Jing Zhang, Emerging role of SETD2 in the development and function of immune cells, Genes & Diseases, Volume 12, Issue 6, 2025, 101622, https://doi.org/10.1016/j.gendis.2025.101622
Funding Information:
National Natural Science Foundation of China 82300929
National Natural Science Foundation of China 82470877
National Natural Science Foundation of China 82100892
Department of Science and Technology of Hubei Province Program Project (China) 2022CFB739
Intramural Research Program of the Central Hospital of Wuhan, Hubei, China 23YJ14
Intramural Research Program of the Central Hospital of Wuhan, Hubei, China 21YJ01
Wuhan Talent Project (China)
Journal
Genes & Diseases